drugset

drugset / Trial / NCT06698822

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

NCT06698822 ↗

Phase 2 Recruiting 20 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.

Timeline

Start: 2025-03-10
Primary completion: 2027-06-19
Completion: 2027-10-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tofacitinib	Small molecule	2 %	Topical

Indications